AcquiSci is confident that its d-OSAB™ technology represents the leading apoptotic therapeutic approach for the treatment of CHF and places the Company in a unique position to rapidly enter and lead this market. Time to commercialization of CHF is the longest of the three target areas, seven (7) to eight (8) years. Never the less, its projected annual revenue by year two of commercialization is $825 million.